Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms

Journal of Virology

Volumn 85, Issue 1, 2011, Pages 43-50

  Ni, Zhenya ^a   Knorr, David A ^a   Clouser, Christine L ^b   Hexum, Melinda K ^a   Southern, Peter ^c   Mansky, Louis M ^b,c   Park, In Hyun ^d   Kaufman, Dan S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHEMOKINE; CYTOKINE; GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL KILLING; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DERIVATIZATION; EMBRYONIC STEM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MEDIATOR; NATURAL KILLER CELL; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VIRUS REPLICATION;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; EMBRYONIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; INDUCED PLURIPOTENT STEM CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78650044727     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01774-10     Document Type: Article

References (53)

1. Alter, G., and M. Altfeld. 2009. NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J. Intern. Med. 265:29-42.
2. Alter, G., M. P. Martin, N. Teigen, W. H. Carr, T. J. Suscovich, A. Schneidewind, H. Streeck, M. Waring, A. Meier, C. Brander, J. D. Lifson, T. M. Allen, M. Carrington, and M. Altfeld. 2007. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 204:3027-3036.
3. Anderson, J. S., S. Bandi, D. S. Kaufman, and R. Akkina. 2006. Derivation of normal macrophages from human embryonic stem (hES) cells for applications in HIV gene therapy. Retrovirology 3:24.
4. Arase, H., N. Arase, and T. Saito. 1995. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. 181:1235-1238.
5. Bandi, S., and R. Akkina. 2008. Human embryonic stem cell (hES) derived dendritic cells are functionally normal and are susceptible to HIV-1 infection. AIDS Res. Ther. 5:1.
6. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
7. Bonaparte, M. I., and E. Barker. 2004. Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood 104:2087-2094.
8. Boulet, S., R. Song, P. Kamya, J. Bruneau, N. H. Shoukry, C. M. Tsoukas, and N. F. Bernard. 2010. HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells. J. Immunol. 184:2057-2064.
9. Caligiuri, M. A. 2008. Human natural killer cells. Blood 112:461-469.
10. Carlsten, M., N. K. Bjorkstrom, H. Norell, Y. Bryceson, T. van Hall, B. C. Baumann, M. Hanson, K. Schedvins, R. Kiessling, H. G. Ljunggren, and K. J. Malmberg. 2007. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 67:1317-1325.
11. Choi, K. D., M. A. Vodyanik, and I. I. Slukvin. 2009. Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+ progenitors. J. Clin. Invest. 119:2818-2829.
12. Choi, K. D., J. Yu, K. Smuga-Otto, G. Salvagiotto, W. Rehrauer, M. Vodyanik, J. Thomson, and I. Slukvin. 2009. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells 27:559-567.
13. Chung, A. W., E. Rollman, R. J. Center, S. J. Kent, and I. Stratov. 2009. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J. Immunol. 182:1202-1210.
14. Cohen, G. B., R. T. Gandhi, D. M. Davis, O. Mandelboim, B. K. Chen, J. L. Strominger, and D. Baltimore. 1999. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10:661-671. (Pubitemid 29302919)
15. Fauci, A. S., D. Mavilio, and S. Kottilil. 2005. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat. Rev. Immunol. 5:835-843.
16. Feng, Q., S. J. Lu, I. Klimanskaya, I. Gomes, D. Kim, Y. Chung, G. R. Honig, K. S. Kim, and R. Lanza. 2010. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells 28:704-712.
17. Freud, A. G., A. Yokohama, B. Becknell, M. T. Lee, H. C. Mao, A. K. Ferketich, and M. A. Caligiuri. 2006. Evidence for discrete stages of human natural killer cell differentiation in vivo. J. Exp. Med. 203:1033-1043.
18. Galic, Z., S. G. Kitchen, A. Kacena, A. Subramanian, B. Burke, R. Cortado, and J. A. Zack. 2006. T lineage differentiation from human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 103:11742-11747.
19. Gervaix, A., D. West, L. M. Leoni, D. D. Richman, F. Wong-Staal, and J. Corbeil. 1997. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc. Natl. Acad. Sci. U. S. A. 94:4653-4658.
20. Grzywacz, B., N. Kataria, M. Sikora, R. A. Oostendorp, E. A. Dzierzak, B. R. Blazar, J. S. Miller, and M. R. Verneris. 2006. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 108:3824-3833.
21. Gupta, N., J. Arthos, P. Khazanie, T. D. Steenbeke, N. M. Censoplano, E. A. Chung, C. C. Cruz, M. A. Chaikin, M. Daucher, S. Kottilil, D. Mavilio, P. Schuck, P. D. Sun, R. L. Rabin, S. Radaev, D. Van Ryk, C. Cicala, and A. S. Fauci. 2005. Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy. Virology 332:491-497.
22. Haase, A. T. 2010. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464:217-223.
23. Hu, B. Y., J. P. Weick, J. Yu, L. X. Ma, X. Q. Zhang, J. A. Thomson, and S. C. Zhang. 2010. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl. Acad. Sci. U. S. A. 107:4335-4340.
24. Hutter, G., D. Nowak, M. Mossner, S. Ganepola, A. Mussig, K. Allers, T. Schneider, J. Hofmann, C. Kucherer, O. Blau, I. W. Blau, W. K. Hofmann, and E. Thiel. 2009. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N. Engl. J. Med. 360:692-698.
25. Iannello, A., M. R. Boulassel, S. Samarani, O. Debbeche, C. Tremblay, E. Toma, J. P. Routy, and A. Ahmad. 2010. Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study. J. Immunol. 184:114-126.
26. Iannello, A., O. Debbeche, S. Samarani, and A. Ahmad. 2008. Antiviral NK cell responses in HIV infection. I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS. J. Leukoc. Biol. 84:1-26.
27. Iannello, A., O. Debbeche, S. Samarani, and A. Ahmad. 2008. Antiviral NK cell responses in HIV infection. II. Viral strategies for evasion and lessons for immunotherapy and vaccination. J. Leukoc. Biol. 84:27-49.
28. Kaufman, D. S. 2009. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood 114:3513-3523.
29. Kaufman, D. S., E. T. Hanson, R. L. Lewis, R. Auerbach, and J. A. Thomson. 2001. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 98:10716-10721.
30. Kitchen, S. G., M. Bennett, Z. Galic, J. Kim, Q. Xu, A. Young, A. Lieberman, A. Joseph, H. Goldstein, H. Ng, O. Yang, and J. A. Zack. 2009. Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice. PLoS One 4:e8208.
31. Ledran, M. H., A. Krassowska, L. Armstrong, I. Dimmick, J. Renström, R. Lang, S. Yung, M. Santibanez-Coref, E. Dzierzak, M. Stojkovic, R. A. J. Oostendorp, L. Forrester, and M. Lako. 2008. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. Cell Stem Cell 3:85.
32. Levy, J. A., A. D. Hoffman, S. M. Kramer, J. A. Landis, J. M. Shimabukuro, and L. S. Oshiro. 1984. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225:840-842.
33. Martin, C. H., P. S. Woll, Z. Ni, J. C. Zuniga-Pflucker, and D. S. Kaufman. 2008. Differences in lymphocyte developmental potential between human embryonic stem cell and umbilical cord blood-derived hematopoietic progenitor cells. Blood 112:2730-2737.
34. Martin, M. P., X. Gao, J. H. Lee, G. W. Nelson, R. Detels, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, J. Trowsdale, M. Wilson, S. J. O'Brien, and M. Carrington. 2002. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31:429-434.
35. Miller, J. S., Y. Soignier, A. Panoskaltsis-Mortari, S. A. McNearney, G. H. Yun, S. K. Fautsch, D. McKenna, C. Le, T. E. Defor, L. J. Burns, P. J. Orchard, B. R. Blazar, J. E. Wagner, A. Slungaard, D. J. Weisdorf, I. J. Okazaki, and P. B. McGlave. 2005. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051-3057.
36. Park, I. H., R. Zhao, J. A. West, A. Yabuuchi, H. Huo, T. A. Ince, P. H. Lerou, M. W. Lensch, and G. Q. Daley. 2008. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451:141-146.
37. Richard, J., S. Sindhu, T. N. Pham, J. P. Belzile, and E. A. Cohen. 2010. HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing. Blood 115:1354-1363.
38. Robinson, W. E., Jr., M. K. Gorny, J. Y. Xu, W. M. Mitchell, and S. Zolla-Pazner. 1991. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J. Virol. 65:4169-4176.
39. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8:299-308.
40. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, M. F. Martelli, and A. Velardi. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100.
41. Scott-Algara, D., V. Arnold, C. Didier, T. Kattan, G. Pirozzi, F. Barre-Sinoussi, and G. Pancino. 2008. The CD85j+ NK cell subset potently controls HIV-1 replication in autologous dendritic cells. PLoS One 3:e1975.
42. Slukvin, I. I., M. A. Vodyanik, J. A. Thomson, M. E. Gumenyuk, and K. D. Choi. 2006. Directed differentiation of human embryonic stem cells into functional dendritic cells through the myeloid pathway. J. Immunol. 176:2924-2932.
43. + cells preferentially develop into endothelial cells. Stem Cells 27:2675-2685.
44. Tian, X., P. S. Woll, J. K. Morris, J. L. Linehan, and D. S. Kaufman. 2006. Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity. Stem Cells 24:1370-1380.
45. Varela-Rohena, A., P. E. Molloy, S. M. Dunn, Y. Li, M. M. Suhoski, R. G. Carroll, A. Milicic, T. Mahon, D. H. Sutton, B. Laugel, R. Moysey, B. J. Cameron, A. Vuidepot, M. A. Purbhoo, D. K. Cole, R. E. Phillips, C. H. June, B. K. Jakobsen, A. K. Sewell, and J. L. Riley. 2008. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat. Med. 14:1390-1395.
46. Vodyanik, M. A., J. A. Bork, J. A. Thomson, and I. I. Slukvin. 2005. Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood 105:617-626.
47. Wang, L., P. Menendez, F. Shojaei, L. Li, F. Mazurier, J. E. Dick, C. Cerdan, K. Levac, and M. Bhatia. 2005. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J. Exp. Med. 201:1603-1614.
48. Ward, J., M. Bonaparte, J. Sacks, J. Guterman, M. Fogli, D. Mavilio, and E. Barker. 2007. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood 110:1207-1214. (Pubitemid 47281418)
49. Ward, J. P., M. I. Bonaparte, and E. Barker. 2004. HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. AIDS 18:1769-1779.
50. Woll, P. S., B. Grzywacz, X. Tian, R. K. Marcus, D. A. Knorr, M. R. Verneris, and D. S. Kaufman. 2009. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 113:6094-6101.
51. Woll, P. S., C. H. Martin, J. S. Miller, and D. S. Kaufman. 2005. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J. Immunol. 175:5095-5103.
52. Yokoyama, W. M., S. Kim, and A. R. French. 2004. The dynamic life of natural killer cells. Annu. Rev. Immunol. 22:405-429.
53. Zamai, L., M. Ahmad, I. M. Bennett, L. Azzoni, E. S. Alnemri, and B. Perussia. 1998. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 188:2375-2380.